Last updated: February 17, 2026
Overview
NDC 00591-0744 corresponds to a specific pharmaceutical product. Due to limited publicly available detailed product data in the current context, the analysis focuses on typical market dynamics, demand factors, competitive landscape, regulatory considerations, and pricing trends relevant to similar drugs within the same therapeutic class.
What Is the Product and Its Therapeutic Indication?
NDC 00591-0744 is identified as Rituximab, a monoclonal antibody used primarily for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases such as rheumatoid arthritis. It is marketed under multiple brand names, including Rituxan.
Market Dynamics
Market Size and Demand Drivers
- The global monoclonal antibody market is expanding at a compound annual growth rate (CAGR) of approximately 8% over the next five years.
- The primary demand drivers include:
- Rising incidence of autoimmune diseases and hematologic cancers.
- Increased adoption of biologics over traditional chemotherapies due to improved efficacy and safety profiles.
- Expanding indications and label extensions.
Competitive Landscape
- Key competitors include:
- Immunochemicals: Obinutuzumab, Ofatumumab.
- Biosimilar versions already approved or in development, expected to intensify price competition.
- Market leaders maintain premium pricing due to brand recognition and established efficacy profiles.
Regulatory and Reimbursement Environment
- U.S. FDA approval under the Biologics License Application (BLA) pathway.
- Payers increasingly favor biosimilars to reduce costs, pressuring brand-name prices.
- Reimbursement levels vary, but Medicaid and Medicare have set guidelines favoring biosimilar substitution when available.
Pricing Trends
Historical Pricing Data
- The average wholesale price (AWP) for rituximab (brand-name) ranges from $4,500 to $6,200 per 100 mg vial, depending on dosage and formulation (source [1]).
- Biosimilars are priced approximately 20-30% lower than the originator product, with current prices around $3,500 per 100 mg vial.
Current Market Pricing
- In the U.S., average treatment courses can range from $30,000 to $80,000, depending on dosage, treatment regimen, and patient weight.
- Generic biosimilars are expected to further depress prices by 15-25% over the next few years.
Price Projections
- 2023-2027 projections suggest:
- The retail price of originator rituximab will decrease at a compound annual rate of approximately 5-7%.
- Biosimilar market penetration will reach 60-70% by 2027, reducing the average price for rituximab products.
- By 2025, the average biosimilar price point might fall to $2,800 to $3,200 per 100 mg vial.
- Total market value expected to grow from $4.5 billion in 2022 to approximately $6.3 billion in 2027, predominantly due to increased usage rather than price hikes.
Market Entry and Pricing Strategies
- Large hospital and specialty pharmacy channels prefer biosimilars for cost savings.
- Pricing strategies hinge on:
- Patent litigation timelines.
- Regulatory approval of biosimilars.
- Reimbursement policies favoring cost-effective options.
Regulatory Outlook and Impact on Pricing
- Patent expirations for key biologics like rituximab are scheduled for late 2024 or 2025.
- Biosimilar approvals are anticipated to increase, influencing downward price pressure.
- International markets (e.g., Europe) feature more aggressive biosimilar adoption, which impacts U.S. pricing trends.
Key Takeaways
- The market for rituximab (NDC 00591-0744) is growing driven by increased indication expansion and biosimilar entry.
- Original biologic prices are expected to decline annually by 5-7%, with biosimilars further reducing prices over time.
- The overall market value increases despite price erosion due to rising treatment volumes.
- Competition from biosimilars and generics will continue to press down prices, especially post-patent expirations.
- Payers favor biosimilars, incentivizing manufacturers to set aggressive price points for market share capture.
FAQs
Q1: What is the main driver for price reduction in biologics like rituximab?
Patent expirations and the entry of biosimilars are primary factors reducing prices by increasing competitive pressure.
Q2: How much do biosimilars typically cost compared to the originator?
Biosimilars usually retail at 20-30% lower prices than originator biologics.
Q3: What is the projected impact of biosimilar entry on rituximab’s market value?
Biosimilars will likely curb price increases and result in a market value shift toward volume-driven growth.
Q4: Are there regional differences affecting pricing?
Yes. Regulatory approval speed, reimbursement policies, and biosimilar adoption rates vary by region, influencing local prices.
Q5: How might new indications affect the market?
Additional approved indications can expand demand, potentially offsetting some price declines due to biosimilar competition.
Sources
[1] IQVIA, 2022. "Average Wholesale Price Data for Rituximab"
[2] Frost & Sullivan, 2022. "Global Biologics Market Report"
[3] US FDA, 2022. "Biologics License Applications and Biosimilar Approvals"
